NHAS
ELVN icon

Novo Holdings A/S’s Enliven Therapeutics ELVN Stock Holding History

Novo Holdings A/S’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.2M Sell
1,280,000
-200,000
-14% -$5.54M 4.07% 8
2025
Q4 		$22.8M Buy
1,480,000
+53,740
+4% +$1.07M 1.77% 20
2025
Q3 		$29.2M Buy
1,426,260
+341,828
+32% +$6.89M 1.88% 18
2025
Q2 		$21.8M Buy
+1,084,432
New +$20.5M 1.54% 20

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Novo Holdings A/S's ELVN Position: Q1 2026 in Review

Novo Holdings A/S reduced its Enliven Therapeutics (ELVN) stake by 14% in Q1 2026, selling an estimated $5.54M and leaving 1,280,000 shares worth $50.2M. The position accounts for 4.07% of the portfolio, ranked #8.

Novo Holdings A/S first reported a position in ELVN in Q2 2025 and has held it in 4 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Novo Holdings A/S held 1,280,000 shares of Enliven Therapeutics worth $50.2M as of Q1 2026.
  • Novo Holdings A/S sold 200,000 Enliven Therapeutics shares in Q1 2026, an estimated $5.54M.
  • Enliven Therapeutics made up 4.07% of Novo Holdings A/S's portfolio in Q1 2026, its #8 holding.
  • Novo Holdings A/S first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Novo Holdings A/S's 13F filing for Q1 2026, filed 15 May 2026.